ArticleFrontiers in oncology2022
Development and validation of cuproptosis-related gene signature in the prognostic prediction of liver cancer.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 44 citations in OpenAlex.
- Development and validation of a cuproptosis-related gene signature for predicting prognosis and drug sensitivity in gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Liver Tumor Prediction using Attention-Guided Convolutional Neural Networks and Genomic Feature Analysis.MethodsX · 2025Article
- The molecular mechanism and therapeutic landscape of copper and cuproptosis in cancer.Signal transduction and targeted therapy · 2025Review
- Targeting cuproptosis for cancer therapy: Focus on the anti-tumor immune system.Cancer pathogenesis and therapy · 2025Review
- Pump-free SERS microfluidic chip based on an identification-competition strategy for ultrasensitive and efficient simultaneous detection of liver cancer-related microRNAs.Biomedical optics express · 2024Article
- lncRNAs as prognostic markers and therapeutic targets in cuproptosis-mediated cancer.Clinical and experimental medicine · 2024Review
- Article
- Copper metabolism and cuproptosis in human malignancies: Unraveling the complex interplay for therapeutic insights.Heliyon · 2024Review
- PANoptosis-related genes function as efficient prognostic biomarkers in colon adenocarcinoma.Frontiers in endocrinology · 2024Article
- Article
- Cuproptosis-Related Ferroptosis genes for Predicting Prognosis in kidney renal clear cell carcinoma.European journal of medical research · 2023Article
- Cuproptosis: mechanisms and links with cancers.Molecular cancer · 2023Review
- A five-cuproptosis-related LncRNA Signature: predicting prognosis, assessing immune function & drug sensitivity in lung squamous cell carcinoma.Journal of Cancer · 2023Article
- An effective prognostic model in colon adenocarcinoma composed of cuproptosis-related epigenetic regulators.Frontiers in pharmacology · 2023Article
- Editorial: Ferroptosis in cancer and Beyond-volume II.Frontiers in molecular biosciences · 2023Article
- A Prognostic Cuproptosis-Related LncRNA Signature for Colon Adenocarcinoma.Journal of oncology · 2023Article
- The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Immune Cell Infiltration in Hepatocellular Carcinoma.Journal of oncology · 2023Article
- Regulatory roles of copper metabolism and cuproptosis in human cancers.Frontiers in oncology · 2023Review
- Commentary: Development and validation of cuproptosis-related gene signature in the prognostic prediction of liver cancer.Frontiers in oncology · 2023Article
- Editorial: Oxidative stress and distinct cell death.Frontiers in physiology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer is a generic term referring to several cancer types arising from the liver. Every year, liver cancer causes lots of deaths and other burdens to the people all over the world. Though the techniques in the diagnosis and therapy of liver cancer have undergone significant advances, the current status of treating liver cancer is not satisfactory enough. The improvement of techniques for the prognosis of liver cancer patients will be a great supplement for the treatment of liver cancer. Cuproptosis is a newly identified regulatory cell death type, which may have a close connection to liver cancer pathology. Here, we developed a prognostic model for liver cancer based on the cuproptosis-related mRNAs and lncRNAs. This model can not only effectively predict the potential survival of liver cancer patients, but also be applied to evaluate the infiltration of immune cell, tumor mutation burden, and sensitivity to anti-tumor drugs in liver cancer. In addition, this model has been successfully validated in lots of liver cancer patients' data. In summary, we wish this model can become a helpful tool for clinical use in the therapy of liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.